ALXN2220

Phase 3Small molecule

ALXN2220 is one of 47 small molecule programs targeting Transthyretin Amyloid Cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transthyretin Amyloid CardiomyopathyActive, not recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Not yet recruiting

TreatmentActive, not recruiting

Transthyretin Amyloid CardiomyopathyPhase 3

Active, not recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Phase 3

Not yet recruiting

TreatmentPhase 2

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

ALXN2220

AstraZeneca

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Niclocide

Bayer

Preclinical

1 4

Alfenta

Jazz Pharmaceuticals

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Clomid

Ferring

Preclinical

1 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Treatment

NCT07213583

Q2 2028

Phase 3Active, not recruiting

Transthyretin Amyloid Cardiomyopathy

NCT06183931

Q1 2029

Phase 2Active, not recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07608354

Q3 2030

Phase 3Not yet recruiting

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07789483

Clinical

Trials by Indication[1]

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)2 trials

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07789483·1,180 enrolled

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07608354·326 enrolled

Treatment1 trial

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

Active, not recruiting·NNeurimmune AG·Phase 2·NCT07213583·35 enrolled

Transthyretin Amyloid Cardiomyopathy1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06183931·1,181 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ALXN2220. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN2220 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN2220. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

ALXN2220

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q1 2029

Q3 2030

Trials by Indication[1]

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)2 trials

Treatment1 trial

Transthyretin Amyloid Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News